Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer

Büntzel, Jens; Glatzel, M.; Küttner, K; Weinaug, R.; Fröhlich, D

doi:10.1053/srao.2002.31356

Cited by 63 publications

(27 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…216 Radioprotectors such as amifostine may also contribute to taste maintenance. [231][232][233][234] Zinc supplementation has shown variable outcomes in taste following cancer therapy. A small trial comparing zinc sulfate (45 mg given 3 times a day) with placebo taken during RT reported an improvement in taste in the study group.…”

Section: Managementmentioning

confidence: 99%

Oral complications of cancer and cancer therapy

Epstein

Thariat

Bensadoun

et al. 2012

CA A Cancer J Clinicians

414

356

View full text Add to dashboard Cite

Answer questions and earn CME/CNEOral complications resulting from cancer and cancer therapies cause acute and late toxicities that may be underreported, underrecognized, and undertreated. Recent advances in cancer treatment have led to changes in the incidence, nature, and severity of oral complications. As the number of survivors increases, it is becoming increasingly recognized that the aggressive management of oral toxicities is needed to ensure optimal long‐term oral health and general well‐being. Advances in care have had an impact on previously recognized oral complications and are leading to newly recognized adverse effects. Here, the authors briefly review advances in cancer therapy, including recent advances in surgery, oral care, radiation therapy, hematopoietic cell transplantation, and medical oncology; describe how these advances affect oral health; and discuss the frequent and/or severe oral health complications associated with cancer and cancer treatment and their effect upon long‐term health. Although some of the acute oral toxicities of cancer therapies may be reduced, they remain essentially unavoidable. The significant impact of long‐term complications requires increased awareness and recognition to promote prevention and appropriate intervention. It is therefore important for the primary oncologist to be aware of these complications so that appropriate measures can be implemented in a timely manner. Prevention and management is best provided via multidisciplinary health care teams, which must be integrated and communicate effectively in order to provide the best patient care in a coordinated manner at the appropriate time. CA Cancer J Clin 2012. © 2012 American Cancer Society.

show abstract

Section: Managementmentioning

confidence: 99%

Oral complications of cancer and cancer therapy

Epstein

Thariat

Bensadoun

et al. 2012

CA A Cancer J Clinicians

414

356

View full text Add to dashboard Cite

show abstract

“…Most of the studies included patients with chemotherapy, [20,26,[30][31][32][33][34][35] some of the studies were confined to radiotherapy, [3,24,28] and a few studied the patients receiving a combination of treatment. [29] Amongst these, the most common chemotherapeutic agent was carboplatin and oxyplatin but, most of them used various chemotherapeutic agents.…”

Section: Resultsmentioning

confidence: 99%

“…Since there was no any restriction in study deign, it ranged from double blind placebo controlled trial to case study report. Out of the 12 reviewed papers half of them were randomized control trials, [3,20,[26][27][28][29] with four of them double blinded, placebo control. [3,20,26,27] Two studies were cross sectional studies, [30,31] and there were three prospective longitudinal studies, [32][33][34] one was a case study, [34] and another one quasi experimental study.…”

Section: Resultsmentioning

confidence: 99%

“…[32] Some drugs like glutamine and amifostine have been examined to prevent and treat dysgeusia, but they did not exhibit positive results. [26,29] The study by Strasser et al suggested no benefits from glutamine on taste change; however, the study was well designed with subjective and objective record of taste change. It is not easy to consider the finding of this study as the author did study on taxane based chemotherapy only, the glutamine used for trial was from specific manufacturer, there was no dose gradient, was done in mixed cancer population, glutamine was tested for prevention only and the dropout rate from the study was high.…”

Section: Discussionmentioning

confidence: 99%

“…[26] Other study by Buntzel et al suggests that amifostine is successful to protect against the acute and late toxicities, including taste alteration, of radiochemotherapy in advanced head and neck cancer. [29] A case study on use of vitamin D was successful to reveal the relationship of impaired taste and serum vitamin D level, however the result has to be interpreted cautiously as it was based on two cases. [34] Megestrol Acetate (MA) was associated with improved taste with p<0.001 in a randomized control trial, but it's hard to interpret the result as the information about the validity of the tool used is lacking, also the dropout rate is high.…”

Section: Other Supplementationmentioning

confidence: 99%

See 2 more Smart Citations

Management of Dysgeusia related to Cancer

Munankarmi

2017

J Lumbini Med Coll

View full text Add to dashboard Cite

a ----------------------------------------------- ABSTRACT:Introduction: Taste change due to cancer is a notorious side effect, adversely affecting appetite and weight. Even though taste change or dysgeusia is one of the major causes of poor nutritional status in cancer survivors, it is not addressed as a significant problem and is often left untreated. The main purpose of this review is to explore current knowledge of pharmacological and behavioral interventions for the treatment of cancer related taste change. Methods: This systematic review was conducted in accordance with PRISMA guidelines to identify original articles on taste change. Multiple databases including; Scopus, Medline, EMBASE, CINAHL, and all databases via Pro quest were searched for original articles or studies related to taste change caused by cancer or its treatment. Relevant articles were subjected to a full text evaluation and assessed by Critical appraisal skills program (CASP) guidelines and the Effective public health practice project (EPHPP) instrument. Results: The search revealed 12 eligible studies, six of which were randomized controlled trials. Most of the studies used a standardized validated tool to measure taste change. Dysgeusia is common in cancer, 14 to 100% cancer patient report it. Pharmacological management with zinc remains inconclusive as one study reports it as beneficial and two other studies reported null effect. Few studies suggested dietary modifications such as use of sugary, salty foods that are helpful to reduce the effect of dysgeusia. Conclusion: Dietary counseling and informing the patient well about self-care strategies before treatment has consistently shown positive results on taste change, with strong statistical power. Other potential treatments for dysgeusia such as zinc, amifostine, and megestrol acetate gave inconsistent results.

show abstract